SANTA CLARA, Calif.--(BUSINESS WIRE)--
Affymetrix, Inc. (AFFX) today announced that it will report operating results for the third quarter of 2013 after market close on Wed., October 30, 2013. The company will hold a conference call on the same day at 5:00pm ET.
A live webcast can be accessed by visiting the investor relations section of the company’s website at www.affymetrix.com. Alternatively, investors and other interested parties may listen to the live conference call by dialing 877-407-8291 (domestic) or 201-689-8345 (international).
A replay of this call will be available from 8:00pm ET on October 30, 2013 until 11:00pm ET on November 6, 2013 at the following numbers: 877-660-6853 (domestic), 201-612-7415 (international). Please enter conference identification number 421484 to access the replay. An archived webcast of the conference call will be available under the investor relations section of the company's website at www.affymetrix.com.
Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of bench-top research into clinical and routine use for human health and wellness.
We strive to provide leadership and support, partnering with our customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes in their quest for answers toward using biology for a better world.
More than 2,300 microarray systems have been shipped around the world and more than 48,000 peer-reviewed papers have been published citing our technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, Vienna and Singapore. The Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit www.affymetrix.com.
- Company Earnings
Doug Farrell, 408-731-5285
Vice President, Investor Relations